SP-624

Phase 2Small molecule

SSirtsei Pharmaceuticals, Inc.

SP-624 is one of 82 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Major Depressive DisorderPhase 2

Active, not recruiting

SchizophreniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Lunesta

3 9

SP-624

SSirtsei Pharmaceuticals, Inc.

Phase 2

1 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Completed·SSirtsei Pharmaceuticals, Inc.·Phase 2·NCT04479852·319 enrolled

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Recruiting·SSirtsei Pharmaceuticals, Inc.·Phase 2·NCT06254612·456 enrolled

Schizophrenia1 trial

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Completed·SSirtsei Pharmaceuticals, Inc.·Phase 1·NCT04510298·27 enrolled

Major Depression1 trial

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Recruiting·SSirtsei Pharmaceuticals, Inc.·Phase 1·NCT06570369·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SP-624. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SP-624 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SP-624. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sirtsei Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSirtsei Pharmaceuticals, Inc.

SP-624

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder2 trials

Schizophrenia1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News